| Identification | Back Directory | [Name]
SR2516 | [CAS]
1061353-68-1 | [Synonyms]
SR2516
VS4817
CS-1780
SR-2516
VS-4718
PND1186
SR 2516
SR-2156
PND 1186
PND-1186
PND1186 10MG
PND-1186, >=98%
PND-1186,SR-2156
VS-4718(PND1186)
SR2516 USP/EP/BP
PND-1186 (SR-2516
PND-1186 (VS-4718)
SR 2516 PND-1186 (VS-4718)
PND 1186 - SR 2516 | VS 4718
PND-1186;VS-4718;PND 1186;PND1186
VS-4718, CT-VS4718, PND-1186, SR 2516
SR-2516; PND 1186; PND1186; SR 2516; SR2516
SR-2516;PND 1186;PND1186;SR 2516;SR2516;VS-4718;VS 4718;VS4718
2-(2-(2-methoxy-4-morpholinophenylamino)-5-(trifluoromethyl)pyridin-4-ylamino)-N-methylbenzamide
2-[[2-[[2-Methoxy-4-(4-morpholinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyridinyl]amino]-N-methylbenzamide
Benzamide, 2-[[2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyridinyl]amino]-N-methyl-
2-{[2-{[2-methoxy-4-(4-morpholinyl)phenyl]amino}-5-(trifluorometh Yl)-4-pyridinyl]amino}-n-methylbenzamide Hydrochloride (1:1) | [Molecular Formula]
C25H26F3N5O3 | [MDL Number]
MFCD28125506 | [MOL File]
1061353-68-1.mol | [Molecular Weight]
501.5 |
| Chemical Properties | Back Directory | [Boiling point ]
654.0±55.0 °C(Predicted) | [density ]
1.334±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
≥50.2 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH | [form ]
solid | [pka]
14.58±0.46(Predicted) | [color ]
White to gray |
| Hazard Information | Back Directory | [Uses]
PND-1186 is a FAK inihbitor which selectively promotes tumor cell apoptosis in 3D environments. | [Synthesis]
General procedure for the synthesis of 2-((2-((2-methoxy-4-morpholinophenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)-N-methylbenzamide from 2-methoxy-4-morpholinophenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)-N-methylbenzamide: In a microwave tube, 2-{[2-chloro-5- (trifluoromethyl)-4-pyridinyl]amino}-N-methylbenzamide (Intermediate 1, 50 mg, 0.152 mmol) was mixed with 2-methoxy-4-morpholinoaniline (148 mg, 0.607 mmol), 1M hydrochloric acid (0.303 mL, 0.303 mmol), 1,4-dioxane (0.2 mL) and water (2.5 mL). The mixture was placed in a microwave reactor and irradiated at 170°C for 25 minutes. After completion of the reaction, the crude product was collected by filtration and the filtrate was purified by reversed-phase high performance liquid chromatography (HPLC) to afford the target compound 2-((2-((2-methoxy-4-morpholinophenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)-N-methylbenzamide (35.5 mg, 0.071 mmol, 46.7% yield). Mass spectrum (MS): molecular weight of molecular formula C25H26F3N5O3 (M) = 471.48, (M+H)+ =472; 1H NMR (400 MHz, methanol-d4) δppm 2.88 (s, 3H), 3.05-3.14 (m, 4H), 3.78-3.91 (m, 7H), 6.45 (s, 1H), 6.52 ( dd, J=8.59,2.53Hz, 1H), 6.64 (d, J=2.53Hz, 1H), 7.03-7.13 (m, 1H), 7.30 (d, J=8.59Hz, 1H), 7.40-7.50 (m, 2H), 7.61 (dd, J=7.83,1.26Hz, 1H), 8.10 (s, 1H). | [in vivo]
PND-1186 (30 mg/kg or 100 mg/kg; subcutaneously; injected subcutaneously in the neck region) inhibits 4T1 subcutaneous tumor growth by induction of apoptosis[1]. | Animal Model: | BALB/c mice[1] | | Dosage: | 30 mg/kg or 100 mg/kg | | Administration: | Injected (100 μL) subcutaneously in the neck region; every 12 h (twice-daily, b.i.d.) for 5 days. | | Result: | 100 mg/kg treatment significantly reduced final 4T1 tumor weight 2-fold whereas 30 mg/kg treatment slightly reduced final tumor weight but was not significantly different compared to control. |
| [target]
FAK | [storage]
Store at -20°C | [References]
[1] Patent: WO2009/105498, 2009, A1. Location in patent: Page/Page column 27-28 |
|
|